Topical Application of Eupatilin Ameliorates Atopic Dermatitis-Like Skin Lesions in NC/Nga Mice
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background: Atopic dermatitis (AD) is an inflammatory skin disorder with severe pruritus. Despite advancements in medicine, therapeutic treatments for AD are still limited. Eupatilin (5,7-dihydroxy-30,40,6-trimethoxyflavone) is one of the lipophilic flavonoids from Artemisia umbelliformis Lam. and Artemisia genipi Weber. Objective: Although it has been reported to act a role in improving inflammation, its action on AD is uncertain. In this study, we examined the role of eupatilin on AD-like skin lesions in NC/Nga mice. Methods: 2,4-dinitrochlorobenzene was repeatedly applied to the ear of NC/Nga mice to produce AD-like skin lesions. Eupatilin (1%, once a day for 5 consecutive days/week) was applied topically for four weeks for the evaluation of its therapeutic effects. Results: 1% eupatilin cream significantly reduced the clinical severity score of AD-like lesions, compared to the vehicle (p＜0.005). A histopathological analysis revealed that 1% eupatilin cream significantly decreased the mast cell infiltration as well as inflammatory cell infiltration, compared to the vehicle (p＜0.005). We showed that 1% eupatilin cream significantly reduced the expression of thymic stromal lymphopoietin, tumor necrosis factor-α, interleukin-4, and interleukin-19, but not interferon-γ, compared to the vehicle (p＜0.005). Conclusion: Considering the therapeutic reaction of eupatilin on AD-like lesions as in this study, the substance has a promising to be an adjuvant topical agent for the control of AD.
Abstract
Background: Atopic dermatitis (AD) is an inflammatory skin disorder with severe pruritus. Despite advancements in medicine, therapeutic treatments for AD are still limited. Eupatilin (5,7-dihydroxy-30,40,6-trimethoxyflavone) is one of the lipophilic flavonoids from Artemisia umbelliformis Lam. and Artemisia genipi Weber. Objective: Although it has been reported to act a role in improving inflammation, its action on AD is uncertain. In this study, we examined the role of eupatilin on AD-like skin lesions in NC/Nga mice. Methods: 2,4-dinitrochlorobenzene was repeatedly applied to the ear of NC/Nga mice to produce AD-like skin lesions. Eupatilin (1%, once a day for 5 consecutive days/week) was applied topically for four weeks for the evaluation of its therapeutic effects. Results: 1% eupatilin cream significantly reduced the clinical severity score of AD-like lesions, compared to the vehicle (p＜0.005). A histopathological analysis revealed that 1% eupatilin cream significantly decreased the mast cell infiltration as well as inflammatory cell infiltration, compared to the vehicle (p＜0.005). We showed that 1% eupatilin cream significantly reduced the expression of thymic stromal lymphopoietin, tumor necrosis factor-α, interleukin-4, and interleukin-19, but not interferon-γ, compared to the vehicle (p＜0.005). Conclusion: Considering the therapeutic reaction of eupatilin on AD-like lesions as in this study, the substance has a promising to be an adjuvant topical agent for the control of AD.
참고문헌 (25)
- Thomas Bieber, "Atopic Dermatitis", Annals of Dermatology, 22(2), pp.125~137 (2010), 대한피부과학회
- Bao L, "IL-4 up-regulates epidermal chemotactic, angiogenic, and pro-inflammatory genes and down-regulates antimicrobial genes in vivo and in vitro:relevant in the pathogenesis of atopic dermatitis", Cytokine, 61, pp.419~425 (2013)
- Leung DY, "Cellular and immunologic mechanisms in atopic dermatitis", J Am Acad Dermatol, 44, pp.S1~S12 (2001)
- Leung DY, "New insights into atopic dermatitis", J Clin Invest, 113, pp.651~657 (2004)
- Blume-Peytavi U, "Optimizing the treatment of atopic dermatitis in children: a review of the benefit", risk ratio of methylprednisolone aceponate, 2011, pp.25, 508~515
- 이지현, "Use of Emollients in Atopic Dermatitis: A Questionnaire Survey Study", Annals of Dermatology, 26(4), pp.528~531 (2014), 대한피부과학회
- Hengge UR, "Adverse effects of topical glucocorticosteroids", J Am Acad Dermatol, 54, pp.1~15 (2006)
- Choi EJ, "Eupatilin protects gastric epithelial cells from oxidative damage and down-regulates genes responsible for the cellular oxidative stress", Pharm Res, 25, pp.1355~1364 (2008)
- Lee S, "Eupatilin inhibits H(2)O(2)-induced apoptotic cell death through inhibition of mitogen-activated protein kinases and nuclear factor-kappaB", Food Chem Toxicol, 46, pp.2865~2870 (2008)
- Choi EJ, "Eupatilin exhibits a novel anti-tumor activity through the induction of cell cycle arrest and differentiation of gastric carcinoma AGS cells", Differentiation, 77, pp.412~423 (2009)
- Lee SH, "Inhibitory effect of eupatilin and jaceosidin isolated from Artemisia princeps in IgE-induced hypersensitivity", Int Immunopharmacol, 7, pp.1678~1684 (2007)
- Kim JY, "Eupatilin blocks mediator release via tyrosine kinase inhibition in activated guinea pig lung mast cells", J Toxicol Environ Health A, 68, pp.2063~2080 (2005)
- Jin H, "Animal models of atopic dermatitis", J Invest Dermatol, 129, pp.31~40 (2009)
- Fujii Y, "Characterization of a 2,4-dinitrochlorobenzene-induced chronic dermatitis model in rats", Skin Pharmacol Physiol, 22, pp.240~247 (2009)
- Jung KE, "Effects of topically applied rapamycin and mycophenolic acid on TNCB-induced atopic dermatitis-like skin lesions in NC", Nga mice, 2015, pp.26, 432~438
- 김주련, "Eupatilin Ameliorates Collagen Induced Arthritis", Journal of Korean Medical Science, 30(3), pp.233~239 (2015), 대한의학회
- Kawakami T, "Mast cells in atopic dermatitis", Curr Opin Immunol, 21, pp.666~678 (2009)
- Kitagaki H, "Immediate-type hypersensitivity response followed by a late reaction is induced by repeated epicutaneous application of contact sensitizing agents in mice", J Invest Dermatol, 105, pp.749~755 (1995)
- Leonard WJ, "TSLP: finally in the limelight", Nat Immunol, 3, pp.605~607 (2002)
- Soumelis V, "Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP", Nat Immunol, 3, pp.673~680 (2002)
- Homey B, "Cytokines and chemokines orchestrate atopic skin inflammation", J Allergy Clin Immunol, 118, pp.178~189 (2006)
- Bao L, "Interleukin-4 up-regulation of epidermal interleukin-19 expression in keratinocytes involves the binding of signal transducer and activator of transcription 6 (Stat6) to the imperfect Stat6 sites", Immunology, 143, pp.601~608 (2014)
- Myles IA, "Signaling via the IL-20 receptor inhibits cutaneous production of IL-1β and IL-17A to promote infection with methicillin-resistant Staphylococcus aureus", Nat Immunol, 14, pp.804~811 (2013)
- Bieber T, "Atopic dermatitis", N Engl J Med, 358, pp.1483~1494 (2008)
- Rudikoff D, "Atopic dermatitis", Lancet, 351, pp.1715~1721 (1998)